Safety aspects of antiepileptic drugs-focus on pharmacovigilance

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 1, 2012, Pages 11-20

  Landmark, Cecilie Johannessen ^a,b   Johannessen, Svein I ^c,d  

^a Faculty of Health Sciences   (Norway)

^b OSLO METROPOLITAN UNIVERSITY   (Norway)

^c National Center for Epilepsy   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Antiepileptic drugs; Efficacy; Pharmacology; Pharmacovigilance; Safety

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ESLICARBAZEPINE ACETATE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PERAMPANEL; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; QUETIAPINE; RETIGABINE; RUFINAMIDE; STIRIPENTOL; SULTIAME; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

APLASTIC ANEMIA; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); CONFUSION; CONGENITAL MALFORMATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; DRUG MONITORING; DRUG QUALITY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG UTILIZATION; DRUG WITHDRAWAL; EPILEPSY; FOLLOW UP; HUMAN; HYPONATREMIA; HYPOTHERMIA; LEUKOPENIA; LIVER TOXICITY; MEDLINE; MONOTHERAPY; NEUROPATHIC PAIN; OSTEOMALACIA; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT SAFETY; PHARMACOEPIDEMIOLOGY; PREGNANCY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; RISK FACTOR; SHOULDER HAND SYNDROME; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; SUDDEN DEATH; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; THERAPY DELAY; VISUAL FIELD DEFECT;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTICONVULSANTS; DATABASES, FACTUAL; DRUG INTERACTIONS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACOVIGILANCE; REGISTRIES;

EID: 84855353952     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2269     Document Type: Review

References (104)

1. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356(9237): 1255-1259.
2. Toledano R, Gil-Nagel A. Adverse effects of antiepileptic drugs. Sem Neurol 2008; 28(3): 317-327.
3. Azar NJ, Abou-Khalil BW. Considerations in the choice of an antiepileptic drug in the treatment of epilepsy. Sem Neurol 2008; 28(3): 305-316.
4. Perucca E. An introduction to antiepileptic drugs. Epilepsia 2005; 46Suppl. 4: 31-37.
5. Johannessen Landmark C. Relations between mechanisms of action and clinical efficacy of antiepileptic drugs in non-epilepsy conditions. CNS Drugs 2008; 22: 27-47.
6. Tsiropoulos I, Gichangi A, Andersen M, et al. Trends in utilization of antiepileptic drugs in Denmark. Acta Neuro Scand 2006; 113(6), 405-411. Erratum in: Acta Neurol Scand 2006; 114(1): 70.
7. Savica R, Beghi E, Mazzaglia G, et al. Prescribing patterns of antiepileptic drugs in Italy: a nationwide population-based study in the years 2000-2005. Eur J Neurol 2007; 14(12): 1317-1321. Erratum in: Eur J Neurol 2008; 15(3): 313.
8. Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders: A population-based study of prescriptions. Epilepsy Res 2009; 87: 31-39.
9. Hollingworth SA, Eadie MI. Antiepileptic drugs in Australia: 2002-2007. Pharmacoepidemiol Drug Saf 2010; 19(1): 82-89.
10. WHO library cataloguing-in-publication data. The importance of pharmacovigilance. Safety monitoring of medicinal products. ISBN: 9241590157 (2002). Accessed April 2010 at:
11. World Health Organization (WHO) collaborating centre, ATC classification system, version 2008. Accessed August 2011 at:
12. Kälviäinen R, Nousiainen I. Visual field defects with vigabatrin: epidemiology and therapeutic implications. CNS Drugs 2001; 15(3): 217-230.
13. van Grootheest K, van Puienbroek EP, de Jong-van den Berg LT. Do pharmacists' reports of adverse drug reactions reflect patients' concerns? Pharm World Sci 2004; 26(3): 155-159.
14. Strandell J, Caster O, Bate A, Norén N, Edwards IR. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf 2011; 34(3): 253-266.
15. Strandell J, Wahlin S. Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database. Eur J Clin Pharmacol 2011; 67(6): 633-641.
16. Suzuki A, Andrade RJ, Bjornsson E, et al. Drugs associated with hepatotoxicity and their frequency of liver adverse events in VigiBase: unified list based on international collaborative work. Drug Saf 2011; 33(6): 503-522.
17. Norén SK, Nordin K, Edwards IR. Suspected adverse drug reactions reported for chldren worldwide: an exploratory study using VigiBase. Drug Saf 2011; 34(5): 415-428.
18. Tsiropoulos I, Andersen M, Hallas J. Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf 2009; 18(6): 483-91.
19. Iorio ML, Moretti U, Colcera S, et al. Use and safety profile of antiepileptic drugs in Italy. Eur J Clin Pharmacol 2007; 63(4): 409-415.
20. Bondon-Guitton E, Sommet A, Montastruc IL. French Association of Regional Pharmacovigilance database. Confusion, a rather serious adverse reaction with valproic acid: a review of the French Pharmacovigilance database. Pharmacopsychiatry 2009; 42(2): 61-66.
21. Ryan M, Adams AG, Larive LL. Hyponatremia and leukopenia associated with oxcarbazepine following carbamazepine therapy. Am J Health Syst Pharm 2001; 58(17): 1637-1639.
22. Buggy Y, Layton D, Fogg C, Shakir SA. Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia 2010; 51(5): 818-829.
23. Aurich-Barrera B, Wilton L, Brown D, Shakir S. Paediatric postmarketing pharmacovigilance using prescritpion-event monitoring: comparison of the adverse event profiles of lamotrigine prescribed to children and adults in England. Drug Saf 2010; 33(9): 751-763.
24. Acharya NV, Pickering RM, Wilton LW, Shakir SA. The safety and effectiveness of newer antiepileptics: a comparative postmarketing cohort study. J Clin Pharmacol 2005; 45(4): 385-393.
25. Lampl C, Schweiger C, Haider B, Lechner A. Pregabalin as mono- or add-on therapy for patients with refractory chronic pain: a post-marketing prescription-event monitoring study. J Neurol 2010; 257(8): 1265-1273.
26. Knudsen JF, Sokol GH, Flowers CM. Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy. J Clin Pharm Ther 2008; 33(5): 513-519.
27. van Grootheest K, Olsson S, Couper M, de Jong-van den Berg L. Pharmacists' role in reporting adverse drug reactions in an international perspective. Pharmacoepidemiol Drug Saf 2004; 13(7): 457-464.
28. Gedde-Dahl A, Harg P, Stenberg-Nilsen H, Buajordet M, Granas AG, Horn AM. Characteristics and quality of adverse drug reaction reports by pharmacists in Norway. Pharmacoepidemiol Drug Saf 2007; 16(9): 999-1005.
29. Morrison-Griffiths S, Walley TJ, Park BK, Breckenridge AM, Pirmohamed M. Reporting of adverse drug reactions by nurses. Lancet 2003; 361(9366): 1347-1348.
30. [No authors listed] Patient reporting improves pharmacovigilance. Prescrire Int 2008; 17(98): 241-242.
31. De Langen J, van Hunsel F, Passier A, de Jong-van den Berg L, van Grootheest K. Adverse drug reaction reporting by patients in the Netherlands: three years of experience. Drug Saf 2008; 31(6): 515-524.
32. FDA-alert (1/31/2008, Updated 12716/2008). Information for healthcare professionals: Suicidal behavior and ideation and antiepileptic drugs. Accessed October 2009 at:
33. Olesen JB, Hansen PR, Erdal J, et al. Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiol Drug Saf 2010; 19 (5): 518-524.
34. Mula M, Bell GS, Sander JW. Suicidality in epilepsy and possible effects of antiepileptic drugs. Curr Neurol Neurosci Rep 2010; 10(4): 327-332.
35. Patorno E, Bohn RL, Wahl PM, et la. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA 2010; 303 (14): 1401-1409. Erratum in: JAMA 2010; 303(22): 2252.
36. Andersohn F, Schade R, Willich SN, Garbe E. Use of antiepileptic drugs in epilepsy and the risk of self-harm or suicidal behavior. Neurology 2010; 75(4): 335-340.
37. Arana A, Wentworth CE, Ayuso-Mateos JL, Arellano FM. Suicide-related events in patients treated with antiepileptic drugs. N Eng J Med 2010; 363(6): 542-551.
38. Stefanello S, Marín-Léon L, Fernandes PT, Li LM, Botega NJ. Psychiatric comorbidity and suicidal behavior in epilepsy: a community-based case-control study. Epilepsia 2010; 51(7): 1120-1125.
39. Mula M, Sander JW. Antiepileptic drugs and suicidality. Much ado about very little? Neurology 2010; 75(4): 300-301.
40. Van der Heijden PG, van Puijenbroek EP, van Buuren S, van der Hofstede JW. On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios. Stat Med 2002; 21(14): 2027-2044.
41. Bandekar MS, Anwikar SR, Kshirsagar NA. Quality check of spontanous adverse drug reaction reporting forms of different countries. Pharmacoepidemiol Drug Saf 2010; 19(11): 1181-1185.
42. Frau S, Font Pous M, Luppino MR, Conforti A. Risk Management Plans: are they a tool for improving drug safety? Eur J Clin Pharmacol 2010; 66(8): 785-790.
43. Karouni M, Arulthas S, Larsson PG, Rytter E, Johannessen SI, Johannessen Landmark C. Psychiatric comorbidity in patients with epilepsy: a population-based study. Eur J Clin Pharmacol 2010; 66(11): 1151-1160.
44. Johannessen Landmark C, Fossmark H, Larsson PG, Rytter E, Johannessen SI. Antiepileptic drug use in epilepsy-a population-based study. Epilepsy Res 2011; 95(1-2): 51-59.
45. Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009; 72(5): 419-425.
46. Ridsdale L, Charlton J, Ashworth M, Richardson MP, Gulliford MC. Epilepsy mortality and risk factors for death in epilepsy: a population-based study. Br J Gen Pract 2011; 61(586): 271-278.
47. Ackers R, Murray ML, Besag FM, Wong IC. Prioritizing children's medicines for research: a pharmaco-epidemiological study of antiepileptic drugs. Br J Clin Pharmacol 2007; 63(6): 689-687.
48. Van de Vrie-Hoekstra NW, de Vries TW, van den berg PB, Brouwer OF, de Jong-van den Berg LT. Antiepileptic drug utilization in children from 1997-2005-a study from the Netherlands. Eur J Clin Pharmacol 2008; 64(10): 1013-1020.
49. Ackers R, Besag FM, Wade A, Murray ML, Wong IC. Changing trends in antiepileptic drug prescribing in girls of child-bearing potential. Arch Dis Child 2009; 94(6): 443-447.
50. Hsia Y, Neubert A, Sturkenboom M, et al. Comparison of antiepileptic drug prescribing in children in three European countries. Epilepsia 2010; 51(5): 789-796.
51. Oteri A, Trifirò G, Gagliostro MS, et al. Prescribing pattern of antiepileptic drugs in an Italian setting of elderly outpatients: a population-based study during 2004-07. Br J Clin Pharmacol 2010; 70(4): 514-522.
52. Johannessen Landmark C, Fossmark H, Larsson PG, Rytter E, Johannessen SI. The prescription registry and abuse of pregabalin. Tidsskr Nor Laegeforen 2011; 131(3): 223.
53. Johannessen Landmark C, Larsson PG, Rytter E, Johannessen SI. Elucidating pregabalin and the Prescription Register. Tidsskr Nor Laegeforen 2011; 131: 800-801.
54. Caster O, Edwards IR, Norén GN, Lindquist M. Earlier discovery of pregbalin's dependence potential might have been possible. Eur J Clin Pharmacol 2011; 67(3): 319-320
55. Mattsson P, Tomson T, Eriksson O, Brännström L, Weitoft GR. Sociodemographic differences in antiepileptic drug prescriptions to adult epilepsy patients. Neurology 2010; 74(4): 295-301.
56. Patel H, Toe DC, Bruke S, Rasu RS. Anticonvulsant use after formulary status change for brand-name second-generation anticonvulsants. Am J Manag Care 2010; 16(8): 197-204.
57. Patsalos P, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs-best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49(7): 1239-1276.
58. Johannessen SI, Johannessen Landmark C. Value of therapeutic drug monitoring in epilepsy. Expert Rev Neurother 2008; 8: 929-939.
59. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second and third generation antiepileptic drugs. Exp Rev Neurother 2010; 10(1): 1-23.
60. Johannessen SI, Johannessen Landmark C. Antiepileptic drug interactions-Basic principles and clinical implications. Current Neuropharm 2010; 8: 254-267.
61. Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed? Clin Pharmacokinet 2006; 458: 1061-1075.
62. Tomson T, Lukic S, Ohman I. Are lamotrigine kinetics altered in menopause? Observations from a drug monitoring database. Epilepsy Behav 2010; 19(1): 86-88.
63. Hirsch LJ, Arif H, Buchsbaum R, et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007; 48(7): 1351-1359.
64. Reimers A, Skogvoll E, Sund JK, Spigset O. Lamotrigine in children and adolescents: the impact of age on its serum concentrations and on the extent of drug interactions. Eur J Clin Pharmacol 2007; 63(7): 687-692.
65. Reimers A. Trends and changes in the clinical use of lamotrigine. Pharmacoepidemiol Drug Saf 2009; 128: 132-139.
66. Andersson ML, Björkhem-Bergman L, Lindh JD. Possible drug-drug interaction between quetiapine and lamotrigine - evidence from a Swedish TDM database. Br J Clin Pharmacol 2011; 72(1): 153-156.
67. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61(4): 570-571.
68. Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45(4): 351-363.
69. Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Expert Rev Neurother 2007; 7: 179-193.
70. Tomson T, Battino D. Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clin Pharmacokinet 2007; 46: 209-219.
71. De Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced in lamotrigine pharmacokinetics: A monotherapy study. Neurology 2004; 63: 571-573.
72. Öhman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure 2008; 17(2): 199-202.
73. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006; 47(3): 504-509.
74. Petrenaite V, Sabers A, Hansen-Schwartz J. Seizure deterioration in women treated with oxcarbazepine during pregnancy. Epilepsy Res 2009; 84(2-3): 245-249.
75. Öhman I, Vitols S, Luef G, Söderfeldt B, Tomson T. Topiramate kinetics during delivery, in the neonatal period, and lactation: preliminary observations. Epilepsia 2002; 43: 1157-1160.
76. Westin AA, Nakken KO, Johannessen SI, Reimers A, Lillestølen KM, Brodtkorb E. Serum concentration/dose ratio of topiramate during pregnancy. Epilepsia 2009; 50: 480-485.
77. Öhman I, Sabers A, de Flon P, Luef G, Tomson T. Pharmacokinetics of topiramate during pregnancy. Epilepsy Res 2009; 87(2-3): 124-129.
78. Tomson T, Palm R, Källén K, et al. Pharmacokinetics of levetiracetam during pregnancy, delivery, in the neonatal period, and lactation. Epilepsia 2007; 48: 1111-1116.
79. Westin AA, Reimers A, Helde G, Nakken KO, Brodtkorb E. Serum concentration/dose ratio of levetiracetam before, during and after pregnancy. Seizure 2008; 17: 192-198.
80. López-Fraile IP, Cid AO, Juste AO, Modrego PJ. Levetiracetam plasma level monitoring during pregnancy, delivery, and postpartum: clinical and outcome implications. Epilepsy Behav 2009; 15(3): 372-375.
81. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - new opportunities for research in pharmacoepidemiology in Norway. Norwegian J Epidemiol 2008; 18(2): 129-136. Available at: or
82. Tomson T, Dahl ML, Kimland E. Therapeutic drug monitoring of antiepileptic drugs for epilepsy. Cochrane Database Syst Rev 2007; 1: CD002216.
83. Sirot JE, van der Velden JW, Rentsch K, Eap CB, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006; 29(9): 735-768.
84. Tornes L, Harden CL. Antiepileptic drug pregnancy registries: do the latest findings concur? Therapy 2010; 7(5): 517-526.
85. Meador K, Reynolds MW, Crean S, et al. Pregnancy outcomes in women with epilepsy: a systematic review and meta-analysis of published pregnancy registries and cohorts. Epilepsy Res 2008; 81(1): 1-13.
86. Eurap Study Group. Utilization of antiepileptic drugs during pregnancy; comparative patterns in 38 countries based on data from the EURAP registry. Epilepsia 2009; 50(10): 2305-2309.
87. Harden CL. Antiepileptic drug teratogenesis: what are the risks for congenital malformations and adverse cognitive outcomes? Int Rev Neurobiol 2008; 83: 205-213.
88. Meador KJ, Baker GA, Browning N, et al. Cognitive function at 3years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009; 360(16): 1597-1605.
89. Vajda FJ, Hitchcock AA, Grahan J, O'Brian TJ, Lander CM, Eadie MJ. The teratogenic risk of antiepileptic drug polytherapy. Epilepsia 2010; 51(5): 805-810.
90. Tomson T, Batino D, Bonizzoni E, et al. for the EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011; 10(7): 609-617.
91. Holmes LB, Mittendorf R, Shen A, Smith CR, Hernandez-Diaz S. Fetal effects of anticonvulsant polytherapies: Different risks from different drug combinations. Arch Neurol 2011, Jun 13, Epub ahead of print
92. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006; 77(2): 193-198.
93. Hunt S, Craig J, Russell A, et al. Levetiracetam in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2006; 67(10): 1876-1879.
94. Vajda FJ, Hollingworth S, Graham J, et al. Changing patterns of antiepileptic drug use in pregnant Australian women. Acta Neurol Scand 2010; 121(2): 89-93.
95. Meador KJ, Penovich P, Baker GA, et al. Antiepileptic drug use in women of childbearing age. Epilepsy Behav 2009; 15(3): 339-343.
96. Tomson T, Battino D, Craig J, et al. Pregnancy registries: differences, similarities, and possible harmonization. Epilepsia 2010; 51(5): 909-915.
97. Kloster R, Engelskjøn T. Sudden unexpected death in epilepsy (SUDEP): a clinical perspective and a search for risk factors. J Neurol Neurosurg Psychiatry 1999; 67(4): 439-444.
98. Nashef L, Ryvlin P. Sudden unexpected death in epilepsy (SUDEP): update and reflections. Neurol Clin 2009; 27(4): 1063-1074.
99. Duncan S, Brodie MJ. Sudden unexpected death in epilepsy. Epilepsy Behav 2011, Epub ahead of print
100. Ackers R, Besag FM, Hughes E, Squier W, Murray ML, Wong IC. Mortality rates and causes of death in children with epilepsy prescribed antiepileptic drugs: a retrospective cohort study using the UK General Practice Research Database. Drug Saf 2011, Jun 13, Epub ahead of print.
101. Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol 2008; 7 (11): 1021-1031.
102. Harden CL, Pennell PB, Koppel BS et al. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50(5): 1247-1255.
103. Harden CL, Meador KJ, Pennell PB, et al. American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes: Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50(5): 1237-1246.
104. Harden CL, Hopp J, Ting TY, et al. American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy-Focus on pregnancy (an evidence-based review): I. Obstetrical complications and change in seizure frequency: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009; 50(5): 1229-1236.